P56 Prolonged benefit of filgotinib in patients with ulcerative colitis in SELECTION
P56 Prolonged benefit of filgotinib in patients with ulcerative colitis in SELECTION
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
IntroductionFilgotinib (FIL) is an oral, JAK1 preferential inhibitor approved for the treatment of patients with UC. In the phase 2b/3 SELECTION trial (NCT02914522), FIL 200 mg (FIL200) was effective in inducing and maintaining clinical remission vs placebo (PBO) in patients with UC. This post hoc analysis of SELECTION data further evaluated the pr...
Alternative Titles
Full title
P56 Prolonged benefit of filgotinib in patients with ulcerative colitis in SELECTION
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2828544261
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2828544261
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2023-BSG.128
